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with zero-fluoroscopy approach for regular
supraventricular tachycardia in patients with
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Abstract
Patients with structural heart disease (SHD) are more difficult to ablate than those with a structurally healthy heart. The reasonmay be
technical problems. We compared periprocedural data in unselected patients (including SHD group) recruited for zero-fluoroscopy
catheter ablation (ZF-CA) of supraventricular arrhythmias (SVTs).
Consecutive adult patients with atrioventricular nodal reentry tachycardia (AVNRT), accessory pathways (AP), atrial flutter (AFL),
and atrial tachycardia (AT) were recruited. A 3-dimensional electroanatomical mapping system (Ensite Velocity, NavX, St Jude
Medical, Lake Bluff, Illinois) was used to create electroanatomical maps and navigate catheters. Fluoroscopy was used on the
decision of the first operator after 5minutes of unresolved problems.
Of the 1280 patients ablated with the intention to be treated with ZF approach, 174 (13.6%) patients with SHD (age: 58.2±13.6;
AVNRT: 23.9%; AP: 8.5%; AFL: 61.4%; and AT: 6.2%) were recruited. These patients were compared with the 1106 patients with
nonstructural heart disease (NSHD) (age: 51.4±16.4; AVNRT: 58.0%; AP: 17.6%; AFL: 20.7%; and AT: 3.7% P .001). Procedural
time (49.9±24.6 vs 49.1±23.9minutes, P= .55) and number of applications were similar between groups (P=0.08). The rate of
conversion from ZF-CA to fluoroscopy was slightly higher in SHD as compared to NSHD (13.2% vs 7.8%, P= .02) while the total time
of fluoroscopy and radiation doses were comparable in the group of SHD and NSHD (P= .55; P= .48).
ZF-CA is feasible and safe in majority of patients with SHD and should be incorporated into a standard approach for SHD; however,
the procedure requires sufficient experience.
Abbreviations: AFL = atrial flutter, AVNRT = atrioventricular nodal reentry tachycardia, CS = coronary sinus, EPS =
electrophisiology study, GUCH = grown-up congenital disease, NSHD = nonstructural heart defects or disease, SHD = structural
heart defects or diseases, SVT = supraventricular arrhythmia, ZF-CA = zero-fluoroscopy catheter ablation.
Keywords: adult congenital heart disease, radiation exposure, radiofrequency catheter ablation, structural heart disease,
supraventricular tachyarrhythmia
1. Introduction
Significant progress has been made in percutaneous catheter
ablation (CA) for supraventricular arrhythmias (SVTs) over the
last 3 decades, with significant reductions in complications and
improvements in efficacy.[1–5] However, the use of fluoroscopy
for catheter navigation and monitoring during most interven-
tional cardiovascular procedures and CAs exposes patients and
medical staff to potentially dangerous, cumulative doses of
ionizing radiation.[6–13]
Although several techniques, approaches, and regulations have
been recommended for limiting radiation exposure, the medical
staff is working with a substantial risk of irradiation associated
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with cumulative exposure.[5–8] Reducing or eliminating exposure
is highly recommended for patients in several cases, such as
pregnancy, young age, cancer, skin disorders, and obesity, and
for those undergoing repetitive procedures especially for cardiac,
cardiothoracic, or vertebral columns anomalies.[9–11]
Considerable development has been made given that 3D-
electroanatomical mapping (3D-EAM) systems have been
implemented that precisely enable the creation of a 3D cardiac
anatomy and the real-time navigation of catheters without the
need of fluoroscopy.[14–16]
In recent years, many scientific studies have been published on
the experience of implementing procedures with significantly
reduced fluoroscopy (near-ZF) or zero-fluoroscopy (ZF) ap-
proach.[13–20]
The literature reviews so far indicate that most authors report
their experience with ZF in patients without a structural heart
disease (SHD). Patients with any SHD, including subgroups, that
is: organic heart diseases; ischemic/nonischemic dilated cardio-
myopathy and other cardiomyopathies; anatomical defects;
grown-up congenital heart disease or adult congenital heart
disease (GUCH/ACHD); and hypertrophic cardiomyopathy, and
those with previous cardiac surgery for valvular heart disease or
past coronary artery bypass grafting or severe thoracic anomalies
seem to pose a real challenge for electrophysiologists.[21]
Moreover, in some of randomized trials on ZF or near-ZF
approach, patients with abovementioned conditions were
routinely excluded.[22]
The purpose of this study was compared periprocedural data in
consecutive patients recruited from a prospective registry
including cases of ZF for CA of SVTs. Further, periprocedural
data of patients with SHDs were compared with those of patients
with nonstructural heart diseases (NSHDs).
2. Patients and methods
Data were obtained from a prospective standardized multicenter
CA registry from January 2012 to February 2017. Seven centers
were included. In all, 1280 consecutive unselected adult patients
(mean age, 52.3±16.2 years) with a final diagnosis of SVT or
supraventricular substratewere recruited. The conditions included
atrioventricular nodal reentry tachycardia (AVNRT), accessory
pathway, atrial flutter (AFL), and atrial tachycardia. The only
contraindications for ZF were cardiac implantable electronic
devices, planned pulmonary vein isolation (PVI) procedure, and
post-PVI arrhythmias. SHDwas not the primary contraindication
for following the ZF approach. The data of 174 patientswith SHD
were compared with those of 1106 patients with NSHD. All
patients underwent routine blood tests, electrocardiography,
detailed echocardiography, and standardized history taking (basic
clinical symptoms)prior to the procedure. For the assessmentof the
frequencyofbasic clinical symptomsor their intensity, a scale in the
range of 1 to 10 was created.
In all cases, the 3D-EAM system (Ensite Velocity, NavX, St
Jude Medical, Lake Bluff, Illinois) was used to create the
electroanatomical maps and navigate catheters. Routinely, no
other detailed imaging technique was used before ablation apart
from transthoracic or transesophageal echocardiography (if
needed). Two femoral vein introducers were used for catheter
insertion; when these failed, the left femoral, subclavian, or
jugular internal vein was used. The procedures were performed
under light sedation, while the catheters were routinely
introduced under local anesthesia.
This study was performed with the consent of the Bioethics
Committee in accordance with the Declaration ofHelsinki as well
as approved by the Bioethics Committee of the University of
Rzeszów No.5/4/2017.
Data were collected from the ELEKTRA registry and RARE-A-
CAREgistry. All patients or their corresponding representatives
gave informed consent before the procedure. All authors had full
access to the data and take full responsibility of the integrity of the
data. Further, all authors have read and agreed to the manuscript
as written.
The study was conducted in EP Labs equipped for immediate
use of fluoroscopy. None of the intervention team used lead-
protective aprons during the procedure, although such equip-
ment was always available in case of need for fluoroscopy. No
intracardiac or transesophageal echocardiography was per-
formed during the procedure.
Procedures were performed only by a highly experienced team
of 3 advanced electrophysiologists and 3 middle-advanced
fellows. All procedures including early implementation period
of ZF approach by 3 advanced electrophysiologists were included
into analysis.
2.1. Standard electrophisiology study (EPS) and zero-
fluoroscopy catheter ablation (ZF-CA) approach
The protocols for the simplified approach and ZF have been
reported earlier.[13,23]
The simplified 2-catheter femoral access approach included the
following: the use of 2 catheters, an ablation catheter, and a
nonsteerable decapolar diagnostic catheter (APT Medical Inc.,
Shenzen, China, St. Jude Medical, St. Paul, MN or Biotronik,
Berlin, Germany); standardized catheter positioning during the
procedure (decapolar catheter in the coronary sinus [CS] and
mapping/ablation catheter in the right atrium, His region, and
right ventricle); and standardized ventricular and atrial EPS
before and after ablation with a 10 to 15-minute observation
period. If CS cannulation was not achieved within 5minutes, the
decapolar catheter was positioned on the lateral site of the
tricuspid annulus or in the superior vena cava. An electrophysio-
logical recording system (EP-Tracer, Cardio-Tek, Maastricht,
The Netherlands) was used during procedures with standard
filters. Standard settings (max. 60–65 °C and 50 [in AVNRT] –65
W [in AFL]) of the RF generator (Stockert, Biosense-Webster,
Diamond Bar, CA) were used. Mapping was performed by
creating a simplified map with the 3D-EAM system (Ensite
Velocity NavX, St. Jude Medical, Lake Bluff, Illinois). The 3D
map was projected at 30° left anterior oblique and 30° right
anterior oblique positions.[13,23]
If the arrhythmia originated from the left atrium or mitral
annulus, the ablation catheter was inserted through the patent
foramen ovale or retrogradely via the femoral artery.
By definition, the ZF approach was followed as an intention-
to-perform procedure; therefore, the medical staff was not using
lead-protective aprons until fluoroscopywas needed. If necessary,
the fluoroscopy was performed, and the decision wasmade by the
main operator after 5minutes of unresolved navigational issues
observed via catheter monitoring, for safety reasons or the need
for a transseptal puncture. No intracardiac echocardiography
was available in this group. A clear explanation concerning the
reasons for using fluoroscopy was prespecified in the computer
database and registry protocol, and this should be written in the
medical reports and stored in the database. The procedural
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definitions, end-points, and complications were based on
standard clinical definition.[8] Patient status was reported in
the medical reports and stored in the database immediately after
ablation, after 1 day, and before hospital discharge. Only in-
hospital complications were recorded.
2.2. Data collection
All preoperational data were collected prospectively in a
computer database and saved. The data were also collected
during ablation and supplemented with the results of treatment.
2.3. Statistical analysis
The data of patients with SHD were compared with those of
patients with NSHD. All results were subjected to a statistical
analysis. Data were presented as mean (SD) and percentages (%).
The Student t testwasused to compare differences between groups.
All analyses were made using the licensed Statistica 13.1 package.
All tests were statistically significant when “P” was <.05.
3. Results
The study population consisted of 1280 consecutive patients with
SVT; of which, 174 patients had SHD. The baseline character-
istics of the study groups are presented in Table 1.
On studying the scores for clinical symptoms, we noted that
SHD patients presented with significantly higher exercise
intolerance (P< .001) and more frequent palpitations (P= .008)
than NSHD patients, while other symptom intensities (such as
those for dyspnea, chest pain, and dizziness) were similar in both
groups (P> .05). Moreover, the incidence for syncope was
similar. SHD patients had significantly worse heart failure
parameters than NSHD patients (P< .001).
A detailed analysis of 174 SHD patients (Table 2) showed that
the organic heart diseases group was most commonly studied
(58.6%) and consisted of patients with various types of
cardiomyopathies, mitral or aortic valve anomalies, aortic
aneurysms, Ebstein anomaly, or dextroversion and patients
who had previously undergone percutaneous coronary inter-
ventions due to acute coronary syndromes. The next group was
of postsurgery patients (17.8%) including those who had
undergone coronary artery bypass grafting and mitral or aortic
valvuloplasty (or replacement). Another group consisted of
patients with significant thorax anomalies (13.7%), and the last
group comprised GUCH patients (9.7%). In this group, there
were individuals after atrial septal defect (ASD 2) and ventricular
septal defect (VSD) closure. Some of the patients had at least 2 or
more SHDs but the most advanced type was considered during
classification.
Analysis of different types of SVT suggested that in SHD
patients, AFL (61.3%) was the most common, while in NSHD
patients, AVNRT (57.7%) was the most common. In both
groups, atrial tachycardia was the least likely to be observed.
Only in NSHD group frequent symptomatic premature ventric-
ular contraction/ventricular tachycardia (1.3%) were addition-
ally ablated during the same session. The remaining results are
shown in Table 3.
Next, several basic parameters during EPS and ablation in
SHD and NSHD patients were compared (Table 4). Procedural
time was similar between patients with SHD and NSHD (49.9±
24.6 vs 49.1±23.9minutes, P= .55).
The rate of conversion from ZF-CA to fluoroscopy and failed
procedure were slightly higher in SHD as compared to NSHD
(13.2% vs 7.8% P= .02). The number of applications as well as
total procedural time for CA, total time of fluoroscopy, and
radiation exposure were similar in both groups, and differences
Table 1
General characteristic patients with structural heart disease and nonstructural heart disease.





























BMI 28.2±5.8 26.0±5.4 <.001
Male patients 591 (45.3%) 118 (70.2%) 473 (41.6%) <.001
Basic clinical symptoms (score 1–10)
Exercise intolerance 5.3±3.8 6.1±3.8 5.1±3.9 <.001
Dyspnea 4.5±3.1 4.7±3.1 4.5±3.2 .31
Chest pain 1.6±2.9 1.7±3.1 1.6±2.9 .54
Palpitations 7.3±3.8 6.6±4.0 7.4±3.8 .01
Fatigue 3.7±3.8 4.0±4.0 3.6±3.8 .16
Dizziness 3.8±3.2 3.9±3.3 3.8±3.2 .59
Presyncope 3.3±3.3 3.2±3.2 3.3±3.3 .76
Syncope 0.7±2.1 0.5±1.8 0.7±2.1 .34
Echocardiographic findings
EF, % 60.6±8.9 48.9±13.2 62.7±5.7 <.001
LVIDD, mm 48.9±6.1 53.3±7.6 48.2±5.5 <.001
LVIDS, mm 32.3±6.4 38.1±8.8 31.2±5.3 <.001
LA, mm 38.2±6.8 42.5±6.9 37.3±6.4 <.001
BMI=body mass index, EF= ejection fraction, LA= left atrium, LVIDD= left ventricle diameter in diastole, LVIDS= left ventricle diameter in systole, NSHD=nonstructural heart disease, SHD= structural heart
disease.
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were not statistically significant (P> .05). However, there were
significantly higher values in the SHD patients with regard to the
duration of measurement and maximum values for energy and
temperature in RF settings. This difference may be associated
with differences in ablated substrates because in AFL, higher
energy settings were required.
ZF approach was completed in 91.4% of 1280 subjects with
SVT. There was significant increase in conversion to fluoroscopy
in SHD (P= .02) and the indications for fluoroscopy in SHD
group were: difficulty in cannulation of CS and instability of
decapolar catheter (n=7), atypical anatomy (n=5), need for
angiographically guided transseptal puncture (n=3), peripheral
vessel puncture with fluoroscopy control (n=3), navigation
problems (n=3), and stabilizing sheath introduction (n=2). In
NSHD, the most 5 frequent indications for fluoroscopy were:
difficulty in cannulation of CS and instability of decapolar
catheter (n=17), instability of ablation catheter (n=12),
monitoring of retrograde approach with aortic valve crossing
and mapping of mitral annulus (n=9), need for angiographically
guided transseptal puncture (n=8), and navigation problems
close to His area (n=7).
After conversion to fluoroscopy, SHD (n=23) and NSHD (n=
87) did not show significant changes in the total time of
fluoroscopy (5.05±5.13 vs 5.59±7.45minutes, respectively [P=
0.75]) as well as radiation doses were comparable in the both
groups.
Major complications were very rarely observed during in-
hospital follow-up: surgically managed groin hematoma (n=1) in
SHD, AV fistula (n=1), surgically managed groin hematoma (n=
1), and prolonged hospital stay for symptomatic pericardial
effusion without tamponade (n=2) in NSHD diagnosed
immediately after successful procedure, but symptoms appeared
during procedure (Table 4).
4. Discussion
To the best of our knowledge, this is the largest registry of ZF
approach as well as the first study comparing SHD and NSHD
patients who underwent ZF-CA for regular SVT and supraven-
tricular substrates.[12,21]
The study showed that the minimally invasive ZF approach
without the use of intracardiac echocardiography (ICE) enabled
treatment without fluoroscopy in majority of patients (>90%)
with a short treatment duration and very high safety profile,
comparable to that reported in previous meta-analysis.[18]
Moreover, the study reports information on differences in CA
of SVT between SHD and NSHD.
SHD patients and medical staff are usually exposed to
radiation several times in the current medical settings.[4–6]
Therefore, efforts to minimize the risk of irradiation should be
validated while developing technologies (eg, 3D-EAM systems)
and progressing in electrophysiology. There are several addition-
al techniques and devices that facilitate the use of ZF approach
during electrophysiological procedures (ICE, TEE, Carto
UNIVU, contact force, imaging integration, and MediGuide).
However, their additional costs and complexity of management
should be taken into account for universal use of these
approaches in EP lab worldwide.
We have been applying the ZF approach during ablation for
several years.[13,23,24] In this study, we present an analysis of a
large group of patients with SHD including adolescent GUCH/
ACHD patients in whom ablation was performed without the use
of fluoroscopy. Other authors are also increasingly reducing
the use of fluoroscopy for ablation; however, SHD is rare and the
incidence of SHD is low in their described groups.[14,15,17]
Table 2
Types of structural heart disease referred for zero-fluoroscopy
catheter ablation.
Primary SHD n=174 (100%)
OHD n=102 (58.6%)
















ASD 2: surgery 12
ASD 2: Amplatzer Septal Occluder 3
ASD 2 & PAPVR 1
VSD: surgery 1
ACHD= adult congenital heart disease, AoV repl.= aortic valve replacement, ASD=2-ostium
secundum atrial septal defect, CABG= coronary artery bypass grafting, CMP= cardiomyopathy,
GUCH=grown-up congenital heart disease, HCM=hypertrophic cardiomyopathy, MV plasty=mitral
valve repair and mitral valve replacement, NCC=noncompaction cardiomyopathy, OHD=organic
heart disease, PAPVR=partial anomalous pulmonary venous return, PCI=percutaneous coronary
intervention, RVH= right ventricular hypertrophy, SHD= structural heart diseases, TA= thorax
anomaly, VSD= ventricular septal defect.
Table 3
Types and numbers of supraventricular tachycardia in subgroups.
SHD n=174 NSHD n=1106 P value Total cohort n=1280
Types of SVT
AVNRT, % 42 (23.9) 656 (58.0) <.001 698 (53.4)
AP, % 15 (8.5) 199 (17.6) .001 214 (16.4)
AFL, % 108 (61.4) 234 (20.7) <.001 342 (26.2)
AT, % 11 (6.2) 42 (3.7) .001 53 (4.0)
PVC/VT, % 0 (0.0) 14 (1.3) – 14 (1.1)
AFL= atrial flutter and interatrial reentry tachycardia, AP= accessory pathways, AT= atrial tachycardia, AVNRT= atrioventricular nodal reentry tachycardia, NSHD=nonstructural heart disease, PVC=premature
ventricular contractions, SHD= structural heart disease, SVT= supraventricular tachycardia, VT= ventricular tachycardia.
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Casella et al[14] demonstrated that patients’ lifetime risks of
cancer incidence and mortality from ZF procedures were reduced
by 96% compared with those from conventional fluoroscopic
procedures. Moreover, the genetic study revealed a substantial
increase in the incidence of mutations associated with an
increasing radiation dose.
The differences in clinical parameters might affect the
prognosis after an ablative approach and these relationships
were described by Sardu et al.[25,26] Cardiac arrhythmias are a
common occurrence after cardiac surgery because a new
arrhythmogenic substrate appears, which is sometimes difficult
to identify.[3] Further, deformities of the spine move the heart
inside the chest, resulting in an atypical anatomy of the heart in
thoracic anomalies and advance scoliosis. This could be a real
challenge for electrophysiologists. In this study, longer ablation
time and parameters of CA were expected for SHD patients than
those for patients with a normal heart anatomy; however, ZF
were successfully and safely incorporated into daily practice in
this group too.
Giaccardi et al[15] in their meta-analysis compared a group of
145 patients treated only under fluoroscopic guidance with 297
patients treated using a nonfluoroscopic electroanatomic map-
ping system (EnSite Velocity). They concluded that the
conventional fluoroscopic technique and the near-zero radiation
(RX) approach provide similar outcomes and may significantly
reduce or eliminate ionizing radiation exposure in radiofrequency
CA. Similar results were presented by Yang et al,[18] although the
results are mainly for patients without SHD.
Further, Mah et al[16] conducted a study in patients aged ≥10
years, weighing ≥35kg, and having a normal cardiac anatomy or
trivial structural heart defects such as bicuspid aortic valve or a
persistent left superior vena cava. Patients were excluded if they
had more than trivial congenital heart disease prior to ablation or
prior to cardiac surgery. However, even with a combination of
3D-EAM and ICE, complete ZF approach was followed only in a
minority of patients.[27–30] In contrast, our study showed ZF
approach feasibility wherein even in the SHD group, procedural
time could be reduced significantly, probably because of lesser
time spent on detailed contour mapping and multichamber 3D
mapping.
In our study group, 174 individuals with SHD were compared
with 1106 patients without SHD. In SHD the most frequent SVT
is AFL, but in NSHDmajority of SVTs are AVNRTs.We showed
that SHD patients have worse exercise capacity and heart
function than NSHD patients. Despite this, the ablation time was
not longer and the number of applications was similar compared
with those for NSHD patients.
Comparison of our previous data on implementation of ZF
approach and current study shows encouraging constant value of
ZF approach performance with very safe, effective, and fast
procedures.[13,31] There are, however, needs for new ZF
dedicated catheters, selective use of ICE (for crossing aortic
valve or need for transeptal puncture), CS catheter stability, and
approach modification (patient preselection or magnetic reso-
nance preprocedural imaging) to decrease number of cross-over
to fluoroscopy.
4.1. Limitations
The present study had few limitations. Firstly, this is not
randomized trial and not all severe SHD or GUCH were treated,
but the study showed routine incorporation of ZF approach in
regular conditions and practice of nonuniversity hospitals.
Furthermore, the conversion to fluoroscopy could be decreased
if the steerable decapolar catheter were used for CS cannulation.
The learning curve of each individual or ZF approaches and EPS
protocol could be different and had potential impact on
procedural data. We did not make a detailed analysis of the
clinical course in the studied groups while Sardu et al[32–34]
showed that ventricular failure as a pump may result in worse
results in patients with metabolic syndrome, diabetes mellitus,
and other diseases that have been ablated. In our study,
echocardiographic parameters were worse in the SHD group
compared to NSHD. We did not study clinical differences or
follow-up because we focused on assessing whether SHD patients
are a more difficult group for ablation or not. The results showed
that SHD patients are not an obstacle to ZF ablation. Finally,
long-term follow-up should be performed (planned) to confirm
the early encouraging results of this registry and cost-effective-
ness. The results of this study and this ZF approach or its
Table 4
Electrophisiology study and ablation parameters.
SHD n=174 NSHD n=1106 P value Total cohort n=1280
Total procedure’s time, min 51.2±26.9 49.9±25.2 .55 50.0±25.4
Number of applications 17.6±13.2 20.2±17.9 .08 19.8±17.5
Time of applications, sec 457.5±356.3 369.2±286.3 <.001 380.5±297.5
Max Watt for applications, W 50.4±11.2 44.1±11.1 <.001 44.9±11.3
Max temp. of applications, °C 58.4±7.1 54.9±7.4 <.001 55.3±7.4
Power settings – Watt, W 57.6±928 52.0±8.1 <.001 52.7±8.4





















DAP, cGy cm2 1620.6±2472.3 1152.4±1650.1 .48 1261.3±1850.5
mGy 97.3±133.9 81.5±89.2 .63 83.7±95.5
∗
Major complications, % 1 (0.5) 4 (0.4) 5 (0.4)
DAP=dose area, mGy=milligray, NSHD=nonstructural heart disease, SHD= structural heart disease.
∗
Major complications: groin hematoma (n=1) in SHD and AV fistula (n=1), groin hematoma (n=1) and pericardial effusion without tamponade (n=2) in NSHD.
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modification is not validated during CA in patients with cardiac
implantable electronic devices.
5. Conclusions
The minimally invasive ZF approach was successfully and safely
implemented in majority of ablation procedures of regular SVT in
SHD andNSHDpatients although this method requires sufficient
experience. Strict ZF approach even in patients with SHD should
be routinely performed but additional imaging modalities or new
devices dedicated for ZF procedures may decrease the rate of
conversion to fluoroscopy and risk of complications and failures.
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